z-logo
open-access-imgOpen Access
The relaxin peptide family – potential future hope for neuroprotective therapy? A short review
Author(s) -
Marius Nistor,
Martin Schmidt,
René Schiffner
Publication year - 2018
Publication title -
neural regeneration research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.93
H-Index - 38
eISSN - 1876-7958
pISSN - 1673-5374
DOI - 10.4103/1673-5374.228713
Subject(s) - relaxin , neuroprotection , medicine , context (archaeology) , pharmacology , bioinformatics , hormone , biology , paleontology
Since its discovery in the 1920's the relaxin peptide hormone family has not only grown in number to now seven members (relaxin-1, relaxin-2, relaxin-3, insulin-like peptide (INSL) 3, INSL4, INSL5 and INSL6), but ever more effects, suchs as vasodilatory, angiogenic, anti-apoptopic, anti-fibriotic and anti-inflammatory, have been linked to them. While relaxin-2 has mainly been investigated in the context of cardiac protection, most comprehensively in the RELAX-AHF and RELAX AHF2 studies, a small number of studies have furthermore assessed the potential neuroprotective effects of especially relaxin-2 and other members of the relaxin family. In this short review we summarise and discuss recent efforts to utilize relaxin hormones for neuroprotection and point out potential future fields of research and translational applications. While many questions still need to be answered, the promising results of the available studies definitely warrant future well-designed studies on neuroprotection by relaxin peptides.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here